一项评估特发性高感觉受试者的Alks 2680的安全性和有效性的研究 (Vibrance-3)
一项2阶段,随机,平行组,双盲,剂量范围调查研究,以评估Alks 2680在特发性高感觉受试者中的安全性和有效性(Fibrance-3)
The purpose of this study is to measure the safety and decrease in daytime sleepiness in subjects with Idiopathic Hypersomnia when taking ALKS 2680 tablets compared with placebo tablets
研究概览
研究类型
注册 (估计的)
阶段
- 阶段2
联系人和位置
学习地点
-
-
-
Bologna、意大利、40139
- Alkermes Investigator Site
-
Milan、意大利、20127
- Alkermes Investigator Site
-
Verona、意大利、37134
- Alkermes Investigator Site
-
-
-
-
-
Prague、捷克语、128 21
- Alkermes Investigator Site
-
-
-
-
-
Alken、比利时、3570
- Alkermes Investigator Site
-
Namur、比利时、5101
- Alkermes Investigator Site
-
-
-
-
Gironde
-
Bordeaux、Gironde、法国、33000
- Alkermes Investigator Site
-
-
Herault
-
Montpellier、Herault、法国、34295
- Alkermes Investigator Site
-
-
Isere
-
Grenoble、Isere、法国、38043
- Alkermes Investigator Site
-
-
-
-
New South Wales
-
Sydney、New South Wales、澳大利亚、2113
- Alkermes Investigator Site
-
-
South Australia
-
Bedford Park、South Australia、澳大利亚、5042
- Alkermes Investigator Site
-
-
Victoria
-
Clayton、Victoria、澳大利亚、3168
- Alkermes Investigator Site
-
-
-
-
Alabama
-
Cullman、Alabama、美国、35055
- Alkermes Investigator Site
-
-
Arizona
-
Phoenix、Arizona、美国、85054
- Alkermes Investigator Site
-
-
Arkansas
-
Little Rock、Arkansas、美国、72211
- Alkermes Investigator Site
-
-
California
-
Los Angeles、California、美国、90025
- Alkermes Investigator Site
-
Redwood City、California、美国、94063
- Alkermes Investigator Site
-
San Francisco、California、美国、94143
- Alkermes Investigator Site
-
-
Colorado
-
Boulder、Colorado、美国、80301
- Alkermes Investigational Site
-
Colorado Springs、Colorado、美国、80918
- Alkermes Investigator Site
-
-
Florida
-
Brandon、Florida、美国、33511
- Alkermes Investigator Site
-
Miami、Florida、美国、33176
- Alkermes Investigator Site
-
Winter Park、Florida、美国、32789
- Alkermes Investigator Site
-
-
Georgia
-
Atlanta、Georgia、美国、30328
- Alkermes Investigator Site
-
Macon、Georgia、美国、31210
- Alkermes Investigator Site
-
Stockbridge、Georgia、美国、30281
- Alkermes Investigator Site
-
-
Illinois
-
Peoria、Illinois、美国、61637
- Alkermes Investigator Site
-
-
Kansas
-
Kansas City、Kansas、美国、66160
- Alkermes Investigator Site
-
-
Massachusetts
-
Boston、Massachusetts、美国、02215
- Alkermes Investigational Site
-
-
Michigan
-
Lansing、Michigan、美国、48911
- Alkermes Investigator Site
-
-
Nebraska
-
Lincoln、Nebraska、美国、68506
- Alkermes Investigator Site
-
-
New Jersey
-
Middletown、New Jersey、美国、07748
- Alkermes Investigator Site
-
-
North Carolina
-
Denver、North Carolina、美国、28037
- Alkermes Investigator Site
-
Huntersville、North Carolina、美国、28078
- Alkermes Investigator Site
-
-
Ohio
-
Canton、Ohio、美国、44718
- Alkermes Investigator Site
-
Cincinnati、Ohio、美国、45245
- Alkermes Investigator Site
-
Cleveland、Ohio、美国、44195
- Alkermes Investigator Site
-
-
Pennsylvania
-
Danville、Pennsylvania、美国、17822
- Alkermes Investigator Site
-
Philadelphia、Pennsylvania、美国、19107
- Alkermes Investigator Site
-
Wyomissing、Pennsylvania、美国、19610
- Alkermes Investigator Site
-
-
South Carolina
-
Columbia、South Carolina、美国、29201
- Alkermes Investigator Site
-
-
Texas
-
Austin、Texas、美国、78731
- Alkermes Investigator Site
-
San Antonio、Texas、美国、78229
- Alkermes Investigator Site
-
Sugar Land、Texas、美国、77478
- Alkermes Investigator Site
-
Sugarland、Texas、美国、77478
- Alkermes Investigator Site
-
-
Wisconsin
-
Madison、Wisconsin、美国、53792
- Alkermes Investigator Site
-
-
-
-
-
Zwolle、荷兰、8025 BV
- Alkermes Investigator Site
-
-
-
-
-
Barcelona、西班牙、8036
- Alkermes Investigator Site
-
Madrid、西班牙、28036
- Alkermes Investigator Site
-
Madrid、西班牙、28043
- Alkermes Investigator Site
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Is willing and able, in the opinion of the Investigator, to understand and comply with protocol requirements, including: lifestyle considerations and restrictions, adherence to contraception guidance, adherence to actigraphy and diary requirements, if receiving treatment for OSA, adherence to primary OSA therapy over the 30 days prior to Visit 1, and throughout the study, including during overnight visits.
- Meets the diagnostic criteria of Idiopathic Hypersomnia according to ICSD-3-TR guidelines, confirmed by the diagnostic evaluations (PSG/MSLT/actigraphy) within the previous 10 years
Exclusion Criteria:
- Has another comorbid sleep disorder or condition that may influence the sleep-wake cycle
- Has a history or presence at Visit 1 of other clinically significant (treated or untreated) illness, disease, abnormality, or surgical procedure that, in the opinion of the Investigator, might compromise subject safety, interfere with any study assessment, or affect the subject's ability to complete the study
- Is currently enrolled in another clinical study or used any investigational drug or device within 30 days prior to Visit 1
- Is currently pregnant, breastfeeding, or is planning to become pregnant during the study
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:双倍的
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:ALKS 2680, 10 mg- Part A
Oral tablet containing 10 mg of ALKS 2680 for once daily administration |
Oral tablet containing ALKS 2680 for daily, oral administration |
|
实验性的:ALKS 2680, 14 mg -Part A
Oral tablet containing 14 mg of ALKS 2680 for once daily administration |
Oral tablet containing ALKS 2680 for daily, oral administration |
|
实验性的:ALKS 2680, 18 mg- Part A
Oral tablet containing 18 mg of ALKS 2680 for once daily administration |
Oral tablet containing ALKS 2680 for daily, oral administration |
|
安慰剂比较:Placebo- Part A
Oral placebo tablet for once daily administration |
Oral placebo tablet for daily administration |
|
实验性的:ALKS 2680 Dose 1- Part B
Oral tablets of ALKS 2680 taken, orally, daily |
Oral tablet containing ALKS 2680 for daily, oral administration |
|
安慰剂比较:Placebo - Part B
Oral tablets of placebo taken, orally, daily |
Oral placebo tablet for daily administration |
研究衡量的是什么?
主要结果指标
结果测量 |
大体时间 |
|---|---|
|
Epworth嗜睡量表(ESS)的变化从基线到第8周的剂量水平
大体时间:长达8周
|
长达8周
|
次要结果测量
结果测量 |
大体时间 |
|---|---|
|
特发性高血压严重程度量表(IHSS)的变化从基线到第8周的剂量水平
大体时间:长达8周
|
长达8周
|
|
Incidence of treatment emergent adverse events
大体时间:Up to 10 weeks
|
Up to 10 weeks
|
合作者和调查者
调查人员
- 研究主任:Medical Director、Alkermes, Inc.
出版物和有用的链接
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.